For example, by encapsulating a STING agonist in exosomes, in which a therapeutic protein such as prostaglandin F2 receptor negative regulator (PTGFRN), is highly expressed in the exosome membrane, ExoSTING was developed to activate the STING pathway in cancer in an antigen-presenting cell-specific manner [277]. Here, PTGFRN is linked to cancer.